In routine clinical practice, tofacitinib shows similar persistence with or without concomitant conventional synthetic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis.
Adalimumab is prescribed to treat autoimmune disorders such as rheumatoid arthritis, ulcerative colitis, Crohn's disease, psoriatic arthritis, ankylosing spondylitis, and juvenile idiopathic arthritis ...
INCHEON, South Korea, May 23, 2025 /PRNewswire/ -- Celltrion, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted an expanded interchangeable designation for YUFLYMA® ...
PHILADELPHIA -- Pfizer has made the case for gaining the coveted "interchangeability" status for its adalimumab biosimilar (Abrilada), a study presented here suggested. A pivotal trial involving ...
PALO ALTO, Calif., Nov. 15, 2022 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF) ("180 Life Sciences" or the "Company"), a clinical-stage biotechnology company today announced that ...
Yuflyma (adalimumab-aaty) and its unbranded version may now be prescribed for HS in patients 12 years and older and for UV in children 2 years and older. The Food and Drug Administration (FDA) has ...
Adalimumab biosimilar AVT02 exhibited comparative efficacy, safety, tolerability, and immunogenicity to the reference drug Humira in patients with moderate-to-severe chronic plaque psoriasis. The ...
Autoinjector recognized by the Arthritis Foundation with Ease of Use Certification Individualized patient support program “HADLIMA For You” available including co-pay support Designed to improve ...
Infliximab Remicaid® Chimeric monoclonal antibody iv. infusion, 3 mg/kg at 0, 2 and 6 weeks followed by maintenance every 4–8 weeks Golimumab Simponi® Human monoclonal antibody sc. injection, 50 mg ...
Dr Oskouei explains the indications for adalimumab and the impact of their extrapolation, as well as differences among adalimumab products. Sonia T. Oskouei, PharmD, BCMAS, DPLA: All biosimilars ...
The appraisal committee considered evidence submitted by AbbVie and a review of this submission by the evidence review group (ERG). See the committee papers for full details of the evidence. The ...
The Appraisal Committee reviewed the data available on the clinical and cost effectiveness of adalimumab for the treatment of psoriasis in adults, having considered evidence on the nature of the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results